Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Material Modification to Rights of Security Holders

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Material Modification to Rights of Security Holders
Item 3.03. Material Modifications to Rights of Security Holders.

Story continues below

The information set forth in Item 5.03 is incorporated herein by reference.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On January 23, 2019, Titan Pharmaceuticals, Inc. (the “Company” or “Titan”) filed a Certificate of Amendment to its Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware for the purpose of effecting a reverse stock split (the “Reverse Split”) of the outstanding shares of the Company’s common stock at a ratio of one (1) share for every six (6) shares outstanding, so that every six (6) outstanding shares of common stock before the Reverse Split represents one (1) share of common stock after the Reverse Split. The Reverse Split, which was approved by Titan’s stockholders at the special meeting of stockholders held on January 23, 2019 (the “Special Meeting”), will be effective at 5:00 p.m. eastern time on January 24, 2019.

Immediately prior to the Reverse Split, there were 77,974,644 shares of common stock outstanding. After the Reverse Split, there will be approximately 12,995,774 shares outstanding. Each stockholder’s percentage ownership interest in the Company and proportional voting power will remain unchanged after the Reverse Split except for minor changes and adjustments resulting from the rounding up of fractional interests. The rights and privileges of the holders of common stock are substantially unaffected by the Reverse Split.

The Reverse Split was effected for the following purposes:

· to enable the Company to meet the criteria for continued listing on the NASDAQ Capital Market (“NASDAQ”), specifically regaining compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2); and
· to provide the Company with available shares for future business and financing transactions.

Copies of the Certificate of Amendment and the press release are attached to this Current Report on Form 8-K as Exhibits 3.1. and 99.1, respectively.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On January 23, 2019, the Company held the Special Meeting to consider and vote upon the following proposals:

(1) to approve the Certificate of Amendment to effect the Reverse Split of the Company’s common stock within a range from 1-for-3 to 1-for-6, with the exact amount to be determined by Titan’s board of directors (the “Board”);

(2) to approve a reduction in the exercise price of outstanding options held by the Company’s employees (other than the named executive officers) and consultants under the Company’s various equity incentive plans with current exercise prices in excess of  $3.50 per share to 110% of the higher of  (i) the average daily volume weighted average closing price of the Company’s common stock on NASDAQ during the 20 trading days immediately preceding the date of the Special Meeting; and (ii) the closing price on the date of the Special Meeting (the “Option Repricing”); and

(3) to approve an amendment to the Company’s 2015 Omnibus Equity Incentive Plan (the “2015 Plan”) to increase the number of shares authorized for issuance thereunder from 3,500,000 to 10,000,000 (the “Plan Amendment”).

Set forth below are the final voting results for each proposal submitted to a vote of the stockholders at the Special Meeting. For more information on the following proposals, see the definitive proxy statement filed by the Company with the Securities and Exchange Commission on December 20, 2018.

Proposal 1: Approve the Reverse Split of the Company’s common stock:

FOR AGAINST ABSTAIN
49,510,090 16,292,520 474,504

As set forth in Item 5.03 above, following the Special Meeting on January 23, 2019, a special committee of the Board established the Reverse Split ratio as 1-for-6.

Proposal 2: Approve the Option Repricing:

FOR AGAINST ABSTAIN BROKER NON-VOTE
10,087,590 9,565,563 754,987 45,868,974

Accordingly, all options with exercise prices in excess of $3.50 ($21.00 post-Reverse Split) held by employees and consultants other than the named executive officers or members of the Board were repriced to $0.258 ($1.55 post-Reverse Split).

Proposal 3: Approve the Plan Amendment to the Company’s 2015 Omnibus Equity Incentive Plan:

FOR AGAINST ABSTAIN BROKER NON-VOTE
10,376,317 9,532,113 499,710 45,868,974

Accordingly, the 2015 Plan has been amended to increase the number of shares authorized for issuance to awards thereunder to 10,000,000 (1,666,667 post-Reverse Split). The amended 2015 Plan is filed as Exhibit 10.1 hereto.

Item 9.01 Financial Statements and Exhibits.

TITAN PHARMACEUTICALS INC Exhibit
EX-3.1 2 tv511477_ex3-1.htm EXHIBIT 3.1   Exhibit 3.1   CERTIFICATE OF AMENDMENT   TO   THE RESTATED CERTIFICATE OF INCORPORATION   OF   TITAN PHARMACEUTICALS,…
To view the full exhibit click here

About Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura. The Company’s drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson’s disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

An ad to help with our costs